A5101490972- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Monoclonal and Polyclonal Antibodies Research
- Peptidase Inhibition and Analysis
- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- PI3K/AKT/mTOR signaling in cancer
- Chronic Lymphocytic Leukemia Research
- Cancer therapeutics and mechanisms
- Sarcoma Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Medical Imaging Techniques and Applications
- Neuroblastoma Research and Treatments
- Statistical Methods in Clinical Trials
- Palliative Care and End-of-Life Issues
- Angiogenesis and VEGF in Cancer
- Frailty in Older Adults
- Chemotherapy-induced cardiotoxicity and mitigation
- Cancer Immunotherapy and Biomarkers
- Testicular diseases and treatments
- Metastasis and carcinoma case studies
Daiichi Sankyo (United States)
2017-2024
Memorial Sloan Kettering Cancer Center
2015-2024
Weill Cornell Medicine
2019
Cornell University
2019
Kettering University
2009-2017
Weatherford College
2015
Grant Medical College and Sir Jamshedjee Jeejeebhoy Group of Hospitals
2015
NYU Langone Health
2011-2014
Quincy Medical Center
2012-2014
Columbia University Irving Medical Center
2014
Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplification, overexpression, or both, a large proportion express low levels of HER2 that may be targetable. Currently available HER2-directed therapies have been ineffective in patients with these "HER2-low" cancers.
HER2-targeted therapies are approved only for HER2-positive breast and gastric cancers. We assessed the safety/tolerability activity of novel antibody-drug conjugate trastuzumab deruxtecan (T-DXd) in 60 patients with pretreated, HER2-expressing (IHC ≥ 1+), non-breast/non-gastric or HER2-mutant solid tumors from a phase I trial (NCT02564900). Most common (>50%) treatment-emergent adverse events (TEAE) were nausea, decreased appetite, vomiting. Two drug-related TEAEs associated fatal outcomes....
This pooled analysis of nine phase I and II trastuzumab deruxtecan (T-DXd) monotherapy studies described drug-related interstitial lung disease (ILD)/pneumonitis in patients treated with T-DXd.Patients who received T-DXd across were included. Investigator-assessed ILD/pneumonitis events retrospectively reviewed by an independent adjudication committee; adjudicated as are summarized.The included 1150 (breast cancer, 44.3%; gastric 25.6%; 17.7%; colorectal 9.3%; other 3.0%). Median treatment...
Primary analysis of the multicenter, open-label, single-arm, phase II DESTINY-Breast01 trial (median follow-up 11.1 months) demonstrated durable antitumor activity with trastuzumab deruxtecan (T-DXd) in patients human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) previously treated emtansine (T-DM1). We report updated cumulative survival outcomes a median 26.5 months (data cut-off 26 March 2021).
Abstract Introduction Rapamycin acts synergistically with platinum agents to induce apoptosis and inhibit proliferation in breast cancer cell lines. Combination of everolimus also known as RAD001 (oral mammalian target rapamycin (mTOR) inhibitor) carboplatin may have activity metastatic triple-negative (TNBC). Methods The primary objective this study was determine clinical benefit rate (CBR), that is (complete remission (CR) + partial (PR) stable disease (SD) lasting ≥6 months) the toxicity...
Abstract The addition of pertuzumab (P) to trastuzumab (H) and neoadjuvant chemotherapy (NAC) has decreased the risk distant recurrence in early stage HER2-positive breast cancer. incidence brain metastases (BM) patients who achieved pathological complete response (pCR) versus those do not is unknown. In this study, we sought BM receiving HP-containing NAC as well survival outcome. We reviewed medical records 526 treated with an HP-based regimen at Memorial Sloan Kettering Cancer Center...
Abstract Objectives Trastuzumab (H) and pertuzumab (P) with standard chemotherapy is approved for use in the neoadjuvant setting human epidermal growth receptor 2 -positive patients. A retrospective analysis was performed of patients treated dose-dense (dd) doxorubicin cyclophosphamide (AC) followed by paclitaxel (T), trastuzumab, (THP) setting. Here, pathologic complete response (pCR) rates are reported. Methods An electronic medical record review conducted HP-based therapy from September...
Abstract Background Trastuzumab and pertuzumab are approved for the neoadjuvant treatment of human epidermal growth receptor 2 (HER2)-positive breast cancer, but cardiac safety data is limited. We report dose-dense doxorubicin cyclophosphamide (AC) followed by paclitaxel, trastuzumab, (THP) in setting adjuvant trastuzumab-based therapy. Methods Fifty-seven patients treated with AC-THP therapy between September 1, 2013, March 2015, were identified. The primary outcome was event rate, defined...
Introduction Cyclin-dependent kinase (CDK) 4/6 inhibitors are cornerstones in the treatment of Hormone Receptor (HR) positive and Human Epidermal Growth factor (HER2) negative metastatic breast cancer. Given their widespread use setting emerging adjuvant setting, studying drug-drug interactions (DDI) these medications is utmost importance.
5582 Background: Monoclonal antibodies Durvalumab (D) and Tremelimumab (T) inhibit binding of programmed cell death ligand 1 (PDL1) to PD1 activation cytotoxic T-lymphocyte-associated protein 4 (CTLA4), respectively, resulting in improved tumor immunosurveillance. There is rationale study D DT based on recent genomic microenvironment evaluation endometrial cancer (EC). Methods: Eligible patients (pts) were randomized or DT. Pts received 1500 mg intravenously (IV) every weeks (wks). therapy...
Abstract Background: DESTINY-Breast04 demonstrated that the HER2 targeting antibody–drug conjugate trastuzumab deruxtecan (T-DXd) significantly prolonged progression-free survival (PFS) and overall (OS) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/in situ hybridization negative) metastatic breast cancer (mBC) pts hormone receptor−positive (HR+) cohort all (HR+ HR-; median PFS, 9.9 5.1 months [mo], hazard ratio: 0.50; OS,...
Abstract Introduction: T-DXd is an antibody-drug conjugate consisting of anti-HER2 antibody, cleavable tetrapeptide-based linker, and a membrane-permeable topoisomerase I inhibitor payload. In patients (pts) with HER2-expressing or -mutated solid tumors, has demonstrated strong antitumor activity manageable safety profile approved for treatment (tx) pts HER2+ metastatic breast cancer (BC) that progressed on ≥2 therapies (US) after chemotherapy (Japan); ILD important identified risk. We...
Taxanes with trastuzumab and pertuzumab for initial treatment of human epidermal growth factor receptor 2 (ERBB2, formerly HER2)-positive metastatic breast cancer is associated improved progression-free survival (PFS) overall survival. While continued use in therapeutic combinations after disease progression standard, the efficacy continuing unknown.To evaluate safety combination gemcitabine prior ERBB2-positive cancer.This a phase single-arm clinical trial dual anti-ERBB2 therapy...